Article

CC chemokine ligand 2 (CCL2) promotes prostate cancer tumorigenesis and metastasis.

Departments of Medicine and Urology, Michigan Center for Translational Pathology and the University of Michigan Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI 48109, United States.
Cytokine & growth factor reviews (Impact Factor: 6.54). 12/2009; 21(1):41-8. DOI: 10.1016/j.cytogfr.2009.11.009
Source: PubMed

ABSTRACT CCL2 is a chemokine known to recruit monocytes and macrophages to sites of inflammation. A growing body of research suggests CCL2 is progressively overexpressed in tumor beds and may play a role in the clinical progression of solid tumors. Cancer cells derived from several solid tumor types demonstrate functional receptors for CCL2, suggesting this chemokine may achieve tumorigenicity through direct effects on malignant cells; however, a variety of normal host cells that co-exist with cancer in the tumor microenvironment also respond to CCL2. These cells include macrophages, osteoclasts, endothelial cells, T-lymphocytes, and myeloid-derived immune suppressor cells (MDSCs). CCL2 mediated interactions between normal and malignant cells in the tumor microenvironment and plays a multi-faceted role in tumor progression.

0 Followers
 · 
200 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Ovarian cancer is strongly associated with a pro-inflammatory leukocyte infiltrate, and high levels of chemokines such as CCL2. CNTO 888, a neutralizing anti-human CCL2 antibody, can inhibit the pro-tumor inflammatory infiltrate and tumor growth. In the present study, we tested the hypothesis that CCL2 neutralization can inhibit tumor growth of ovarian cancer cell line pairs formed by a parental cell line and a non-multi-drug resistant (MDR) paclitaxel-resistant line. Furthermore, we investigated whether mouse stromal CCL2 plays a role in tumor growth promotion. Elevated CCL2 expression was determined by quantitative PCR in three non-MDR paclitaxel resistant (TP) ovarian cancer cell lines ES-2/TP, MES-OV/TP and OVCAR-3/TP, and compared to their related parental cells. Increased CCL2 protein expression levels in vitro and in vivo were confirmed in the drug resistant variants. In order to determine the role of CCL2 on tumor growth upon drug treatment, we established parental and non-MDR paclitaxel resistant cell lines expressing a GFP-luciferase fusion gene. These cells were implanted intraperitoneally (i.p.) and subcutaneously (s.c.) in nude mice. Mice were treated with the anti-human CCL2 antibody (CNTO 888) and the anti-mouse MCP-1 antibody (C1142), orthologous of human CCL2, with and without chemotherapy (paclitaxel or carboplatin). Tumor growth was evaluated by both bioluminescence and caliper measurements. Our results show a significant additive effect of CCL2 blockade on the efficacy of paclitaxel and carboplatin. The mechanism of this therapeutic effect was largely due to inhibition of mouse stromal CCL2. Our findings show that inhibition of CCL2 can enhance paclitaxel and carboplatin treatments of ovarian cancer.
    Molecular Oncology 03/2014; DOI:10.1016/j.molonc.2014.03.016 · 5.94 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Increased CCL2 expression in prostate cancer (PCa) cells enhanced metastasis via macrophage recruitment. However, its linkage to androgen receptor (AR)-mediated PCa progression remains unclear. Here, we identified a previously unrecognized regulation: targeting AR with siRNA in PCa cells increased macrophage recruitment via CCL2 up-regulation, which might then result in enhancing PCa invasiveness. Molecular mechanism dissection revealed that targeting PCa AR with siRNA promoted PCa cell migration/invasion via CCL2-dependent STAT3 activation and epithelial-mesenchymal transition (EMT) pathways. Importantly, pharmacologic interruption of the CCL2/CCR2-STAT3 axis suppressed EMT and PCa cell migration, providing a new mechanism linking CCL2 and EMT. Simultaneously targeting PCa AR with siRNA and the CCL2/CCR2-STAT3 axis resulted in better suppression of PCa growth and metastasis in a xenograft PCa mouse model. Human PCa tissue microarray analysis suggests that increased CCL2 expression may be potentially associated with poor prognosis of PCa patients. Together, these results may provide a novel therapeutic approach to better battle PCa progression and metastasis at the castration resistant stage via the combination of targeting AR with siRNA and anti-CCL2/CCR2-STAT3 signalling.
    EMBO Molecular Medicine 09/2013; 5(9). DOI:10.1002/emmm.201202367 · 8.25 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Increased expression of the chemokine CCL2 in tumor cells correlates with enhanced metastasis, poor prognosis, and recruitment of CCR2(+)Ly6C(hi) monocytes. However, the mechanisms driving tumor cell extravasation through the endothelium remain elusive. Here, we describe CCL2 upregulation in metastatic UICC stage IV colon carcinomas and demonstrate that tumor cell-derived CCL2 activates the CCR2(+) endothelium to increase vascular permeability in vivo. CCR2 deficiency prevents colon carcinoma extravasation and metastasis. Of note, CCR2 expression on radio-resistant cells or endothelial CCR2 expression restores extravasation and metastasis in Ccr2(-/-) mice. Reduction of CCR2 expression on myeloid cells decreases but does not prevent metastasis. CCL2-induced vascular permeability and metastasis is dependent on JAK2-Stat5 and p38MAPK signaling. Our study identifies potential targets for treating CCL2-dependent metastasis.
    Cancer cell 07/2012; 22(1):91-105. DOI:10.1016/j.ccr.2012.05.023 · 23.89 Impact Factor

Preview

Download
0 Downloads
Available from